Authors Disclose Financial Ties to Pharma Firms in Nature Report
Contributing authors involved in research evaluating the normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer have disclosed extensive financial relationships, honoraria, research funding, and advisory roles with numerous pharmaceutical entities, according to disclosures published in Nature.
The disclosures feature research funding, advisory contributions, honoraria, and consulting roles from multiple pharmaceutical companies, including AstraZeneca, Daiichi Sankyo, Merck, and Bristol-Myers Squibb. Contributing authors reported professional connections with a wide array of biotechnology and drug manufacturing firms spanning the industry.
According to the Nature report, author M.C.G. disclosed honoraria, consulting roles, speakers’ bureau participation, research funding, travel accommodations, and uncompensated relationships with entities such as MSD Oncology, AstraZeneca/MedImmune, GSK, Takeda, Roche, Bristol-Myers Squibb, Daiichi Sankyo/AstraZeneca, Regeneron, Pfizer, Blueprint Medicines, Novartis, Sanofi/Aventis, Medscape, Oncohost, Revolution Medicines, Celgene, Seagen, Lilly, Bayer, Janssen, AbbVie, Mirati Therapeutics, Merck, Boehringer Ingelheim, Avion, Gilead Sciences, Genentech, Incyte, Spectrum Pharmaceuticals, Ipsen, Exelixis, MedImmune, and Amgen.
Additional disclosures from contributing authors include M-J.A., who reported financial relationships with AstraZeneca, Lilly, MSD, Takeda, Amgen, Merck Serono, Yuhan, Daiichi Sankyo/AstraZeneca, Alpha Pharmaceutical, and Arcus Ventures.
Author L.P-A. reported leadership and stock ownership in Altum Sequencing and Stab Therapeutics, alongside numerous honoraria, consulting roles, speakers’ bureau positions, institutional research funding, and other relationships with firms including Roche/Genentech, Pfizer, Bristol-Myers Squibb, PharmaMar, BeiGene, GSK, Janssen, Medscape, Regeneron, Boehringer Ingelheim, Novartis, Sanofi, Bayer, Ipsen, Servier, and Merck.
Author A.L. disclosed employment and stock ownership with Boston Scientific, alongside consulting and research funding relationships with AstraZeneca, Leica Biosystems, Novocure, Jazz Pharmaceuticals, MorphoSys, Lilly, Oncocyte, Sanofi/Regeneron, Janssen Oncology, G1 Therapeutics, Molecular Axiom, Daiichi Sankyo Nordics, Bayer, IQVIA, Calithera Biosciences, Dracen, WindMIL, Duality Biologics, and eFFECTOR Therapeutics, as well as pending U.S. provisional patent application No. 63/527,899.
Author M.L.J. reported institutional consulting and advisory roles as well as institutional research funding from organizations including AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, ArriVent Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, D3 Bio, Daiichi Sankyo, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, Gilead Sciences, GSK, Gritstone Bio, Hookipa Biotech, Immunocore, Janssen Oncology, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, Molecular Axiom, Normunity, Novartis, Novocure, Pfizer, Pyramid Biosciences, Revolution Medicines, Sanofi, SeaGen, Synthekine, Takeda, VBL Therapeutics, Adaptimmune, Apexigen, Array BioPharma, Artios, Atreca, Bayer, BeiGene, BerGenBio, BioAtla, Black Diamond Therapeutics, and BerGenBio, according to Nature.